

# Correlation between clinical response and MuSK-Ab changes in patients treated with Rozanolixizumab

Silvia Falso,<sup>1</sup> Sofia Marini,<sup>1</sup> Giuseppe Valenzano,<sup>1</sup> Veronica Morcone,<sup>1</sup> Jacopo Morroni,<sup>2</sup> Martina Marini,<sup>1</sup> Federico Habetswallner,<sup>1</sup> Raffaele Iorio<sup>1,2</sup>

<sup>1</sup>Department of Neuroscience, Università Cattolica del Sacro Cuore; Rome, Italy

<sup>2</sup>Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Rome, Italy

## Objective

Real-world data on rozanolixizumab efficacy in MuSK-MG are lacking. MuSK-Abs belong to the IgG4 subclass and are thought to correlate with disease severity. This study aimed to assess the clinical response to rozanolixizumab in a cohort of MuSK-MG patients and to investigate changes of MuSK-Ab titers using live cell-based assay (L-CBA).

## Materials and Methods

We enrolled MuSK-MG patients treated with rozanolixizumab at our center. Baseline characteristics, clinical efficacy, safety, and biological data were collected. MG-ADL and QMG scores were used to assess clinical efficacy. Steroid dose changes were also evaluated. MuSK-Ab titers were measured at baseline and at the end of first treatment cycle using L-CBA.

## Results




Figure 1. Change of MG-ADL score (A), QMG score (B) and Median Daily Steroid Dose (C) from baseline.




Figure 2. Change of MuSK-Ab titers from baseline.

Comparison of MuSK-IgG levels (detected through L-CBA) in serum samples collected at baseline and at the end of first cycle. MuSK-Ab titers were significantly reduced from baseline ( $p=0.008$ )

## Conclusions

Our findings show that rozanolixizumab is an effective add-on treatment in MuSK-MG, leading to significant reductions in MG-related disability. Further investigations will clarify whether reductions in antibody titers translate to sustained clinical improvements.



24-28 Ottobre 2025  
Padova Congress

55° CONGRESSO  
SOCIETÀ ITALIANA  
DI NEUROLOGIA